Zymeworks Inc. (NASDAQ:ZYME – Get Free Report) insider Paul Moore sold 39,741 shares of Zymeworks stock in a transaction dated Friday, November 13th. The shares were sold at an average price of $26.07, for a total value of $1,036,047.87. Following the sale, the insider owned 33,756 shares of the company’s stock, valued at approximately $880,018.92. This trade represents a 54.07% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.
Zymeworks Price Performance
ZYME opened at $26.24 on Monday. Zymeworks Inc. has a one year low of $18.20 and a one year high of $31.97. The firm has a market capitalization of $1.81 billion, a price-to-earnings ratio of 50.46 and a beta of 1.32. The business has a 50 day simple moving average of $27.32 and a two-hundred day simple moving average of $25.48.
Zymeworks (NASDAQ:ZYME – Get Free Report) last released its quarterly earnings data on Monday, November 9th. The company reported $2.28 earnings per share for the quarter, beating analysts’ consensus estimates of $2.27 by $0.01. Zymeworks had a net margin of 16.10% and a return on equity of 22.23%. The business had revenue of $512.92 million during the quarter, compared to analyst estimates of $227.40 million. During the same period last year, the business earned ($0.26) EPS. Zymeworks’s revenue was up 828.7% compared to the same quarter last year. As a group, sell-side analysts expect that Zymeworks Inc. will post 1.31 EPS for the current fiscal year.
Zymeworks News Summary
These are some of the ZYME news items that stood out recently:
- Positive Sentiment: A report linked Zymeworks’ improved outlook to a milestone payment and a profitable quarter. The company’s latest reported results also beat the cited EPS consensus slightly, while revenue was well above estimates—supportive news, though milestone revenue may not recur. Milestone Payment Lifts Zymeworks Stock Outlook After Profitable Quarter
- Positive Sentiment: Separate reports cited a higher TD Cowen price target, a bullish forecast from Truist, and Zymeworks reaching a new 52-week high after better-than-expected earnings. TD Cowen price target report Truist forecast report New 52-week high report
- Negative Sentiment: HC Wainwright cut its estimates across several upcoming quarters, lowering its FY2026 EPS forecast to $1.19 from $1.51 and moving its FY2027 outlook from $1.32 profit to a projected $0.39 loss. The analyst retained a Buy rating and $56 target, but the revisions signal a less favorable earnings outlook beyond the recent quarter.
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the business. Entropy Technologies LP bought a new stake in Zymeworks in the third quarter valued at $220,000. Jump Financial LLC increased its stake in shares of Zymeworks by 799.1% in the third quarter. Jump Financial LLC now owns 230,236 shares of the company’s stock worth $6,099,000 after acquiring an additional 204,628 shares during the last quarter. HighVista Strategies LLC raised its position in Zymeworks by 4.6% during the third quarter. HighVista Strategies LLC now owns 35,578 shares of the company’s stock valued at $942,000 after acquiring an additional 1,565 shares in the last quarter. Fisher Asset Management LLC grew its stake in Zymeworks by 759.9% in the 3rd quarter. Fisher Asset Management LLC now owns 608,612 shares of the company’s stock valued at $16,122,000 after buying an additional 537,837 shares during the last quarter. Finally, Russell Investments Group Ltd. lifted its position in shares of Zymeworks by 104.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 97,994 shares of the company’s stock worth $2,596,000 after acquiring an additional 50,127 shares during the period. 92.89% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
Several research analysts recently commented on ZYME shares. Stifel Nicolaus set a $46.00 price objective on shares of Zymeworks in a research note on Friday, August 7th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $52.00 price target on shares of Zymeworks in a research report on Friday, October 23rd. Citigroup upped their price objective on shares of Zymeworks from $39.00 to $44.00 and gave the company a “buy” rating in a research note on Wednesday, November 11th. JPMorgan Chase & Co. raised their target price on shares of Zymeworks from $31.00 to $33.00 and gave the stock an “overweight” rating in a research note on Thursday, September 3rd. Finally, Deutsche Bank set a $32.00 price target on Zymeworks in a research report on Wednesday, August 26th. Twelve investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Zymeworks has a consensus rating of “Moderate Buy” and a consensus price target of $43.25.
Read Our Latest Research Report on Zymeworks
About Zymeworks
Zymeworks Inc. is a biotechnology company headquartered in Vancouver, Canada, that develops engineered medicines, with a focus on treatments for cancer and other serious diseases. Its antibody-engineering technologies are designed to create therapies that can engage multiple biological targets or modify immune responses. The company’s lead program is zanidatamab, a HER2-targeted bispecific antibody. In the United States, it is marketed by partner Jazz Pharmaceuticals as Ziihera for certain adults with previously treated, unresectable or metastatic biliary tract cancer.
Featured Articles
- Five stocks we like better than Zymeworks
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.
